This National Cancer Institute (NCI) funding opportunity supports exploratory research projects focused on the early-stage development of highly innovative technologies. The grant aims to foster novel molecular or cellular analysis capabilities crucial for basic and clinical cancer research. Emphasizing a high degree of technical innovation, proposed technologies should target, probe, or assess molecular and cellular features of cancer biology, improving characterizations in the field. Applications must demonstrate potential to significantly advance research in areas like cancer biology, early detection, clinical diagnosis, treatment, control, epidemiology, and address cancer health disparities. This initiative is a core component of the NCI’s broader Innovative Molecular Analysis Technologies (IMAT) Program, driving advancements in understanding and combating cancer.
Opportunity ID: 336709
General Information
Document Type: | Grants Notice |
Funding Opportunity Number: | RFA-CA-22-001 |
Funding Opportunity Title: | Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) |
Opportunity Category: | Discretionary |
Opportunity Category Explanation: | – |
Funding Instrument Type: | Grant |
Category of Funding Activity: | Education Health |
Category Explanation: | – |
Expected Number of Awards: | – |
Assistance Listings: | 93.394 — Cancer Detection and Diagnosis Research |
Cost Sharing or Matching Requirement: | No |
Version: | Synopsis 1 |
Posted Date: | Nov 24, 2021 |
Last Updated Date: | Nov 24, 2021 |
Original Closing Date for Applications: | Sep 22, 2022 |
Current Closing Date for Applications: | Sep 22, 2022 |
Archive Date: | Oct 28, 2022 |
Estimated Total Program Funding: | – |
Award Ceiling: | $150,000 |
Award Floor: | – |
Eligibility
Eligible Applicants: | Private institutions of higher education Public and State controlled institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) Special district governments State governments Independent school districts Public housing authorities/Indian housing authorities For profit organizations other than small businesses County governments City or township governments Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal governments (Federally recognized) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses |
Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
Agency Name: | National Institutes of Health |
Description: | This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic or clinical cancer research. The emphasis of this FOA is on supporting the development of novel capabilities involving a high degree of technical innovation for targeting, probing, or assessing molecular and cellular features of cancer biology. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer biology. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program. |
Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-22-001.html |
Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
OERWebmaster03@od.nih.gov Email:OERWebmaster03@od.nih.gov |
Version History
Version | Modification Description | Updated Date |
---|---|---|
Related Documents
Folder 336709 Full Announcement-RFA-CA-22-001 -> RFA-CA-22-001-Full-Announcement.pdf
Packages
Agency Contact Information: | NIH OER Webmaster OERWebmaster03@od.nih.gov Email: OERWebmaster03@od.nih.gov |
Who Can Apply: | Organization Applicants |
Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
---|---|---|---|---|---|---|
FORMS-G | Use for due dates on or after January 25, 2022 | PKG00270638 | Mar 22, 2022 | Sep 22, 2022 | View |
Package 1
Mandatory forms
336709 RR_SF424_5_0-5.0.pdf
336709 PHS398_CoverPageSupplement_5_0-5.0.pdf
336709 RR_OtherProjectInfo_1_4-1.4.pdf
336709 PerformanceSite_4_0-4.0.pdf
336709 RR_KeyPersonExpanded_4_0-4.0.pdf
336709 RR_Budget_3_0-3.0.pdf
336709 PHS398_ResearchPlan_4_0-4.0.pdf
336709 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
336709 RR_SubawardBudget30_3_0-3.0.pdf
336709 PHS_AssignmentRequestForm_3_0-3.0.pdf